Literature DB >> 9373715

Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis.

K Kuroda1, H Shinkai.   

Abstract

Cultured fibroblasts from patients with systemic sclerosis (SSc) and normal individuals were examined for gene expression of types I and III collagen, decorin, matrix metalloproteinases (MMP) MMP-1, MMP-2, and MMP-3, tissue inhibitors of metalloproteinases (TIMP) TIMP-1 and TIMP-2, urokinase- and tissue-type plasminogen activators (u-PA and t-PA). Fibroblasts from patients with early stage SSC (less than 1 year duration of disease) exhibited higher levels of types I and III procollagen, decorin, MMP-1, MMP-3, TIMP-1, and PAs than those from normal individuals. The gene expression of procollagen alpha 1(I) and TIMP-1 mRNAs were increased, but those of decorin, MMP-1, MMP-2, and MMP-3 were decreased, in fibroblasts from SSc patients with mid-stage SSc (2 to 4 years duration) as compared with those from normal individuals. In contrast, no significant difference in gene expression was found between fibroblasts from normal individuals and from patients with late-stage SSc (more than 6 years duration). These results suggest that gene expression of collagen, decorin, and degrading factors is dynamically modulated during fibrillogenesis. The responses of procollagen alpha 1(I) mRNA to IL-1 and TGF-beta were lower in fibroblasts from SSc patients with early and mid-stage disease, but not in those from patients with-late stage disease, than in control fibroblasts, which indicates that these cytokines may be involved in the earlier phases of fibrosis in SSc.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373715     DOI: 10.1007/s004030050241

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  25 in total

Review 1.  Integrin signaling in fibrosis and scleroderma.

Authors:  H A Gardner
Journal:  Curr Rheumatol Rep       Date:  1999-10       Impact factor: 4.592

2.  Serum levels of soluble CD21 in patients with systemic sclerosis.

Authors:  Manabu Tomita; Takafumi Kadono; Norihito Yazawa; Tomohiko Kawashima; Zenshiro Tamaki; Ryuichi Ashida; Hanako Ohmatsu; Yoshihide Asano; Makoto Sugaya; Masahide Kubo; Hironobu Ihn; Kunihiko Tamaki; Shinichi Sato
Journal:  Rheumatol Int       Date:  2010-10-30       Impact factor: 2.631

3.  Identification of an Association of TNFAIP3 Polymorphisms With Matrix Metalloproteinase Expression in Fibroblasts in an Integrative Study of Systemic Sclerosis-Associated Genetic and Environmental Factors.

Authors:  Peng Wei; Yang Yang; Xinjian Guo; Nainan Hei; Syeling Lai; Shervin Assassi; Mengyuan Liu; Filemon Tan; Xiaodong Zhou
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

4.  Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients.

Authors:  Manuela Indelicato; Valentina Chiarenza; Massimo Libra; Grazia Malaponte; Valentina Bevelacqua; Maurizio Marchini; James A McCubrey; Franca Stivala; Raffaella Scorza; Maria Clorinda Mazzarino
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

5.  Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice.

Authors:  A Nakao; M Fujii; R Matsumura; K Kumano; Y Saito; K Miyazono; I Iwamoto
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

6.  Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.

Authors:  S A Young-Min; C Beeton; R Laughton; T Plumpton; S Bartram; G Murphy; C Black; T E Cawston
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

Review 7.  Matrix metalloproteinases: a review of their structure and role in systemic sclerosis.

Authors:  Wen-jia Peng; Jun-wei Yan; Ya-nan Wan; Bing-xiang Wang; Jin-hui Tao; Guo-jun Yang; Hai-feng Pan; Jing Wang
Journal:  J Clin Immunol       Date:  2012-07-06       Impact factor: 8.317

8.  Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis.

Authors:  C Nishijima; I Hayakawa; T Matsushita; K Komura; M Hasegawa; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

9.  A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.

Authors:  Jennifer L Sargent; Ausra Milano; Swati Bhattacharyya; John Varga; M Kari Connolly; Howard Y Chang; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2009-10-08       Impact factor: 8.551

10.  Modulation of microRNome by Human Cytomegalovirus and Human Herpesvirus 6 Infection in Human Dermal Fibroblasts: Possible Significance in the Induction of Fibrosis in Systemic Sclerosis.

Authors:  Irene Soffritti; Maria D'Accolti; Gloria Ravegnini; Maria-Cristina Arcangeletti; Clara Maccari; Flora De Conto; Adriana Calderaro; Elisabetta Caselli
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.